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The expansion of regulatoryT cells (Treg) is a common event characterizing the vast majority
of human and experimental tumors and it is now well established thatTreg represent a cru-
cial hurdle for a successful immunotherapy. Treg are currently classified, according to their
origin, into thymus-derivedTreg (tTreg) or peripherally inducedTreg (pTreg) cells. Controversy
exists over the prevalent mechanism accounting for Treg expansion in tumors, since both
tTreg proliferation and de novo pTreg differentiation may occur. Since tTreg and pTreg are
believed as preferentially self-specific or broadly directed to non-self and tumor-specific
antigens, respectively, the balance between tTreg and pTreg accumulation may impact
on the repertoire of antigen specificities recognized by Treg in tumors. The prevalence of
tTreg or pTreg may also affect the outcome of immunotherapies based on tumor-antigen
vaccination or Treg depletion. The mechanisms dictating pTreg induction or tTreg expan-
sion/stability are a matter of intense investigation and the most recent results depict a
complex landscape. Indeed, selected Treg subsets may display peculiar characteristics in
terms of stability, suppressive function, and cytokine production, depending on microen-
vironmental signals. These features may be differentially distributed between pTreg and
tTreg and may significantly affect the possibility of manipulating Treg in cancer therapy. We
propose here that innovative immunotherapeutic strategies may be directed at diverting
unstable/uncommittedTreg, mostly enriched in the pTreg pool, into tumor-specific effectors,
while preserving systemic immune tolerance ensured by self-specific tTreg.
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Treg SUPPRESS PRO-TUMORAL INFLAMMATION OR
ANTI-TUMOR RESPONSE
INTRODUCTION
Tumor onset is a very complex process, in which cells of both
innate and adaptive immune system play crucial roles in inhibiting
or fostering tumor development. The awareness that the immune
system could act as an extrinsic tumor suppressor or as a tumor-
sculpting player resulted in the cancer immunoediting theory,
which described the interaction between tumor and host as con-
sisting of three different phases: elimination, equilibrium, and
escape (1). During the last phase of this process, transformed cells
acquire the ability to subvert the control exerted by immune cells
thus originating the clinically evident pathology. The escape is due
to different mechanisms, including reduced immunogenicity (low
expression level of MHC class I and loss of antigen expression),
acquired resistance to the cytotoxic functions of immune cells,
and accumulation in the tumor microenvironment of immuno-
suppressive mediators, like regulatory T cells (Treg) (1). The first
marker to be identified as distinguishing Treg from the other CD4+
T lymphocytes was CD25 (2) and depletion of CD25-positive cells
unveiled anti-tumor immunity in experimental models (3). Few
years later, the transcription factor Forkhead Box P3 (Foxp3) was
indicated as the master regulator of Treg (4, 5). In support of
the crucial roles played by Foxp3 in Treg fate determination and
immune homeostasis, Foxp3 mutations have been recognized as
responsible for human Immune Dysfunction, Polyendocrinopa-
thy, Enteropathy, X-linked (IPEX) syndrome (6, 7), and for the
phenotype of scurfy mutant mice (8), both characterized by
fatal autoimmune lymphoproliferation linked to severe defects
in Treg development/functions. However, very recent data have
demonstrated that the complete development of the Treg lineage
requires the concomitant, Foxp3-independent, establishment of a
Treg-specific pattern of DNA hypomethylation (9).
According to recently proposed recommendations (10), Treg
are classified into two principal subsets based on their develop-
mental origin: thymus-derived Treg (tTreg) develop in the thymus,
while peripherally induced Treg (pTreg) develop in vivo in the
periphery from conventional T cells (Tconv), through a process
called “conversion” (11). Treg can also be induced in vitro (and are
called iTreg) under TGF-β and/or retinoic acid exposure, but their
complete commitment into fully differentiated Treg is still under
debate (12). In physiological conditions, the pool of Treg, encom-
passing both tTreg and pTreg, which represents about the 5–10%
of the circulating CD4+ T lymphocytes, assures peripheral self-
tolerance and prevents exacerbated immune responses (7, 8). A
huge amount of data now demonstrates that tumor onset and pro-
gression perturb Treg homeostasis and lead to increased Treg/Tconv
and Treg/CD8 ratios both in peripheral blood and in the tumor
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microenvironment (13). The accumulation of Treg at tumor sites
may be due to the concomitant or the preferential occurrence of
distinct events, such as the recruitment of Treg from periphery, the
proliferation of pre-existing Treg in the tumor microenvironment,
and the de novo conversion of tumor-infiltrating CD4+ lympho-
cytes (TIL) into pTreg (14, 15). Despite controversy existing over
the dominant suppression mechanism, and despite the incomplete
understanding of the biological meaning of Treg accumulation in
cancer, it is well accepted that Treg are crucial players in tumor
biology and that the modulation of their function is an indis-
pensable requisite for the development of successful anti-tumor
immune-therapies.
MECHANISMS OF Treg SUPPRESSION IN TUMORS
It was recently demonstrated that Treg infiltrating different tissues
have a specific gene signature (16), thus Treg may use peculiar sup-
pression mechanisms in response to microenvironmental stimuli.
This specialization may represent the basis for designing immune
interventions targeting specific Treg functions in a given tissue
while sparing systemic immune homeostasis. Even though a tumor
Treg-specific gene signature has not been delineated yet, some
mechanisms have been described to contribute to Treg suppres-
sion in tumors, which can be clustered in three main types: surface
molecules, enzymatic activities, and cytokines (Figure 1).
Both human and mouse Treg constitutively express on their sur-
face cytotoxic T lymphocyte-associated antigen 4 (CTLA-4), a co-
inhibitory member of the CD28/B7 family, endowed with strong
immune-regulatory properties (17). The relevance of CTLA-4 in
regulating Treg function was demonstrated in several settings,
including autoimmune diseases and different tumor types (18).
A comparative gene expression profile between Treg and Tconv
revealed that Treg specifically up-modulate lymphocyte activation
gene 3 (LAG-3) (19), a homolog of CD4, that binds to MHC
class II on antigen-presenting cells (APCs). LAG-3 is upregu-
lated in tumor-infiltrating Treg and experiments with anti-LAG-3
mAb demonstrated that functional LAG-3 is required for maxi-
mal Treg suppressive function (20, 21). Treg-DC interaction is also
mediated by the transmembrane protein neuropilin-1 (Nrp-1),
expressed on Treg membrane, which ensures the stability of Treg-
DC interaction and allows Treg to efficaciously suppress DC (22).
A study conducted on patients with early-stage cervical tumor
showed that Treg infiltrating the tumor-draining lymph node
of patients with metastasis have a higher expression of several
immune-modulatory molecules, including Nrp-1 (23). The recep-
tor activator of nuclear factor-kB ligand (RANKL), member of the
tumor necrosis factor family, was found to be highly expressed on
Treg isolated from tumor-bearing hosts, and substantial evidence
indicates that RANKL expressed by Treg is involved in the onset of
metastasis in both mammary (24) and prostate tumors (25).
Regulatory T cell suppression may be mediated by enzymatic
activities, such as CD39/CD73 (26, 27), granzyme B, and perforin
(28). CD39 and CD73 are two ecto-enzymes that dephosphory-
late extracellular ATP and generate pericellular adenosine,which in
turn exerts a strong pro-tumorigenic role modulating the function
of numerous tumor-infiltrating immune cells. CD73-deficient
mice develop a stronger anti-tumor immune response compared
to CD73-sufficient mice (29). Treg are also able to control the
FIGURE 1 |Treg suppressive mechanisms in tumor microenvironment.
Treg use different strategies to inhibit target cells within the tumor mass.
Three types of Treg-related molecules can mediate these suppressive
mechanisms: (1) surface molecules (upper panel); (2) enzymes (middle
panel), and (3) cytokines (lower panel). (1) Among the surface molecules
expressed by Treg, CTLA-4, LAG-3, Nrp-1, and RANKL have a
well-demonstrated role in promoting tumor progression, mainly modulating
DC activation and function. In particular CTLA-4 and LAG-3, binding to
CD80/CD86 (B7-1/2), and MHCII respectively, significantly impair DC
capacity to activate Tconv. In addition CTLA-4 promotes IDO expression and
the production of the pro-apoptotic metabolite kynurenine. Nrp-1 instead
stabilizes Treg-DC contact, allowing Treg to adequately suppress DC. Although
the course of action of RANKL is not yet well defined, its expression is
associated to tumor metastatization. (2) The two ecto-enzymes CD39 and
CD73 generate from ATP pericellular adenosine, which is endowed with
strong tolerogenic effects. Also cAMP, similarly to adenosine, interferes
with Tconv activation and survival. Granzyme and perforin induce the
apoptosis of target cells by cytolysis. (3) Treg secrete several
immune-modulatory cytokines, which could directly modulate Tconv
functions (TGF-β, IL-10, and IL-35), or indirectly promote the establishment
of pro-tumorigenic microenvironment (VEGF).
proliferation and function of different immune cells via the Per-
forin pathway (30). In mouse models of melanoma, lymphoma,
and acute myeloid leukemia it has been demonstrated that tumor-
infiltrating Treg, but not naïve Treg, secrete high amounts of both
perforin and granzyme B, which in turn induce NK and CD8+ T
cell death (28).
Immunosuppressive cytokines, like TGF-β and IL-10, are criti-
cal players in Treg biology, being involved in both their differenti-
ation and suppressive potential, especially in tumors. Treg-derived
TGF-β was found relevant in suppression of anti-tumor T cell
response in both mouse (31) and human (32, 33) tumors. IL-10
is a well-known immunosuppressive mediator, and several pieces
of evidence highlight the relevance of Treg-derived IL-10 in con-
trolling inflammation at the mucosal interfaces such as gut and
lung (34, 35). Despite these data, little information is available
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about the roles of Treg-derived IL-10 in tumor microenviron-
ments. We have recently demonstrated that tumor-associated Treg
secrete high amounts of IL-10, which in turn impairs DC migra-
tion to the draining lymph nodes and the mounting of a specific
anti-tumor immune response. This phenotype could be reverted
by stimulating the receptor OX40 on the surface of intratumoral
Treg. Indeed, OX40-triggered Treg showed reduced secretion of IL-
10 as a consequence of the down-modulation of the interferon
regulatory factor 1 (IRF1), a transcription factor active in the IL-
10 promoter (36). Another cytokine recently described as critical
for the full Treg suppressive function is IL-35, formed by Epstein–
Barr-virus-induced gene 3 (Ebi3) and IL-12α (p35) (37). In two
different mouse transplantable tumor models (melanoma and
colon carcinoma), it was observed that Treg secrete abundant IL-
35, thus promoting the differentiation of induced IL-35-secreting
Treg (37). It is well known that tumor growth is associated with
a consistent process of new angiogenesis in response to hypoxia.
A circuit involving tumor hypoxia, Treg recruitment, and angio-
genesis has been recently discovered (38). In the hypoxic tumor
microenvironment, the chemokine axis CCL28–CCR10 plays a
determinant role in the recruitment of Treg, which secrete huge
amounts of vascular endothelial growth factor (VEGF), further
stimulating the new angiogenesis process and the establishment
of a tolerogenic microenvironment (38).
DOUBLE EFFECTS OF Treg ON PROGNOSIS
Since their discovery, Treg were considered one of the main obsta-
cles for tumor clearance, according to their tolerogenic properties
and their accumulation along tumor progression. In this view,
several anti-tumor immune-therapies focus on Treg depletion or
inhibition, in order to “contrasuppress” Treg inhibitory functions
and to block the conversion of non-regulatory cells (non-Treg)
into regulatory cells (15). Reduced Tconv/Treg ratio was observed in
patients with pancreatic tumor (39, 40), breast cancer (39), ovar-
ian cancer (41), Hodgkin lymphoma (42), and melanoma (43).
Increased Treg frequency is generally associated to advanced tumor
stage and poor prognosis, as recently demonstrated in a study
on ovarian cancer (44). In the ascites of patients with advanced
tumor, the percentage of Treg was increased compared to the ascites
of patients with early-stage tumor. Same results were obtained
with the mouse WF-3 transplantable ovarian tumor model, show-
ing augmented percentages of Treg in both spleen and tumor-
associated cells of mice with advanced tumors, compared to naïve
or mice with early lesions. In addition, the treatment of tumor-
bearing mice with the Treg-depleting mAb PC61 (αCD25) reduced
tumor growth and prolonged mice survival (44). Similarly, it has
been demonstrated that Treg number inversely correlated with
the therapy outcome in melanoma patients treated with non-
myeloablative chemotherapy, in combination or not with total
body irradiation, followed by adoptive T cell transfer (45). Respon-
der patients had a lower frequency of Treg in peripheral blood
compared to non-responder patients (45). A study conducted on
patients affected by invasive ductal carcinoma showed a positive
correlation among Treg, Th17, and tumor aggressiveness. These
data imply that Treg and Th17 cells may concomitantly expand
during tumor progression, with Treg mainly suppressing protec-
tive effector T cell proliferation while sparing Th17 proangiogenic
activities, fostering cooperatively tumor progression, and the
metastatic process (46).
Nevertheless, recent data, in particular tumor systems,point out
that Treg may exert a protective role for the host (13, 47, 48). The
connection between tumor and inflammation is a well-assessed
process (49), but now it is clearly emerging that the type of tumor-
associated inflammation imprints the behavior of Treg, becoming
detrimental or beneficial for the host. Type-1 inflammation, char-
acterized by high concentration of IFN-γ and IL-12 and fully
active cytotoxic cells, represents efficient anti-tumor immunity
(49). In this setting, the inhibitory properties of Treg may promote
tumor escape and aggressiveness (47). On the contrary, immune
responses dominated by cytokines like TNF-α, IL-1β, IL-6, IL-23,
and IL-17 act as pro-tumoral mediators (47). In this environment
Treg may suppress a pro-tumoral inflammatory status, thus playing
a protective role for the host (47).
These unexpected anti-tumoral Treg properties were observed
in patients with colorectal cancer (CRC) (50–52). In these patients,
with different tumor stages, a better prognosis and an increased
overall survival were associated with higher infiltration of FOXP3+
T cells compared to patients with a poor tumor outcome. These
data suggested the hypothesis that FOXP3+ T cells could be con-
sidered as an independent prognostic factor for CRC. Following
a strong activation, both conventional CD4+ (53) and CD8+
(54) lymphocytes up-regulate Foxp3 expression in colonic tissue.
These observations indicated that the CRC prognosis positively
correlated with non-regulatory FOXP3+ cells rather than to Treg.
However in vitro suppression assays demonstrated that FOXP3+
cells, isolated from CRC tissues, were endowed with suppressive
functions, confirming their nature as regulatory cells (55). In a
recent study conducted on 65 patients with different stages of CRC,
FOXP3 expression was systematically evaluated in both tumor-
infiltrating lymphocytes and neoplastic cells, and was correlated
to tumor progression and clinical-pathological features (56). From
this study the notion emerged that high FOXP3 expression in
tumor cells correlated with poor tumor outcome, compared to
tumors poorly expressing FOXP3; on the contrary, no correlation
was observed between CRC prognosis and FOXP3 expression by
T cells (56).
A protective role of Treg was also found in head and neck
squamous cell carcinoma (HNSCC) (57). Univariate and mul-
tivariate analysis demonstrated that the locoregional control of
the tumor was positively associated with CD4+FOXP3+ regula-
tory cell infiltration (57). However, also for this type of neoplasia,
there are some discordant data regarding the role of Treg in tumor
progression. Indeed, another study showed that Treg frequency
and suppressive function were higher in the peripheral blood of
tumor-bearing patients than in healthy volunteers (58).
The discrepancies observed in these studies may be due to the
number of patients included, different strategies of analysis and
non-homogeneity of tumor samples (stage, metastasis, etiology).
Certainly, to properly define the role of Treg in tumor outcome,
the new studies should take into account the tumor stage and
the related inflammatory features, depending on the anatomi-
cal localization. In general, those tumors arising from chronic
inflammation, almost at their initial stage, can benefit from the
suppressive properties of Treg. In fact, during the inflammatory
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process, Treg highly accumulate in the site of inflammation such to
prevent exacerbated immune responses and tissue damage, which
are the prelude to neoplastic transformation. On the contrary, in
the presence of an established tumor, Treg may reduce anti-tumor
immunity thus favoring tumor escape. A more specific definition
of Treg contribution in tumor development and progression is
desirable for the design of new and more effective immunothera-
pies, allowing the discrimination among tumors that will benefit
or not from Treg depletion/inhibition.
EVIDENCE FOR pTreg OR tTreg ACCUMULATION IN TUMORS
DISTINGUISHING FEATURES OF pTreg AND tTreg
Many efforts have been recently addressed to the identification
of phenotypic, molecular, and functional features distinguishing
tTreg and pTreg, besides their site of origin (11). Some markers
have been proposed to distinguish pTreg and tTreg, even though
with some limitations: the initial enthusiasm for the suggestion
of Helios as able to identify tTreg (59) has been soon moldered
by the observation of Helios expression in pTreg (60); the recent
finding of the Nrp-1 as a marker of tTreg (61, 62) has application
limited to murine cells, being not expressed on human Treg (63).
Several attempts have been conducted to identify genetic (64–66)
and/or epigenetic signatures distinguishing pTreg and tTreg. The
Treg-specific demethylated region (TSDR) is involved in the sta-
ble commitment of the Treg lineage, and controversy still remains
on whether iTreg or pTreg can efficiently demethylate this region
and become fully committed Treg (66–69). Despite this growing
amount of information, distinguishing the relative contribution
of pTreg and tTreg to immune suppression in physiological and
pathological conditions remains hard. However, some pieces of
evidence have accumulated in the last years that speak in favor of
tTreg or pTreg prevalence or concomitance in tumors.
EVIDENCE FOR tTreg ACCUMULATION IN CANCER
One of the first attempts to distinguish between pTreg conver-
sion and tTreg expansion in cancer was pursued by Bui and col-
leagues who adoptively transferred CD4+CD25+ cells, mixed at
1:10 ratio with CD25-depleted Thy1.1-congenic splenocytes, into
immunodeficient mice bearing a progressive sarcoma (70). The
analysis performed 10 days after tumor injection showed that the
vast majority (around 80%) of tumor-infiltrating CD4+CD25+
cells derived from expansion/recruitment of the transferred Treg,
rather than from conversion of non-Treg. This and other reports,
appeared in the“pre-Foxp3”era, were biased by the idea that CD25
was the most stringent Treg marker and that CD25-depleted cells
represented a suitable precursor population to efficiently detect
de novo generation of pTreg. However, subsequent studies have
demonstrated that the CD25+ subset of Foxp3− Tconv is enriched
in pTreg precursors (69, 71), thus the extent of pTreg differentiation
from CD25-depleted cells represents probably an underestimation
of the actual contribution of pTreg induction in the tumor con-
text. Other authors have shown that tTreg may dominate pTreg
not only quantitatively but also qualitatively, in terms of suppres-
sive function: indeed, IDO+ plasmacytoid dendritic cells, derived
from mouse tumor-draining lymph nodes, were capable to induce
Foxp3+ pTreg at very high levels but were unable to activate
the suppressive function of these cells to an extent comparable
to tTreg (72). Many studies have clearly shown Treg prolifera-
tion (in terms of de novo DNA synthesis and/or cell division) in
tumor-bearing mice or cancer patients, thus indirectly supporting
the idea that expansion of pre-existing tTreg might prevail over
pTreg differentiation in building the tumor-associated Treg pool.
For instance, Treg have been shown to incorporate high levels of
BrdU in tumor-draining lymph nodes and at cancer sites in sev-
eral experimental models (73, 74). A study conducted in patients
with multiple myeloma showed that the TREC content in naive
cells was significantly lower in Treg (identified as CD4+CD25high
cells) than CD4+CD25− or CD25low cells, suggesting that the Treg
pool mainly derived from peripheral expansion rather than recent
thymic emigration (75). However, the observation of high Treg
proliferation at tumor sites cannot be considered as an unequivo-
cal proof of tTreg prevalence over pTreg, since both subsets could
be endowed with the same proliferative potential in vivo. Indeed,
several pieces of evidence indicate that conversion and prolifera-
tion may represent uncoupled and independent events (see pTreg
Development and tTreg Expansion as Independent Processes).
EVIDENCE FOR pTreg INDUCTION IN CANCER
Some studies support the idea that pTreg conversion actually
occurs in tumor-bearing hosts at higher efficiency than in physio-
logical conditions, even if controversy still exists on whether pTreg
may prevail numerically over tTreg at the tumor site. We have in the
past demonstrated that thymectomized and CD25-depleted mice,
subsequently transplanted with carcinoma cells, showed a signifi-
cantly higher Treg recovery in tumor-draining than in contralateral
lymph nodes, suggesting that in tumor-bearing mice the Treg pool
might be replenished mostly by newly derived pTreg than by pro-
liferation of residual Treg. To prove this possibility, CD25-depleted
CD4-purified T cells were transferred into immunocompetent,
Thy1.1-congenic, CT26 tumor-bearing mice. In this setting, we
could show that the transferred cells acquired CD25 and Foxp3
at significantly higher levels in draining lymph nodes, compared
to contralateral lymph nodes of tumor-bearing mice, or to the
lymph nodes of tumor-free mice (76). This result clearly showed
that tumor progression actively promoted the conversion of non-
regulatory precursors into pTreg. Some tumor-derived molecular
signals were found to be involved in tumor-associated conversion.
For instance, in different mouse models, tumor cells have been
shown to induce in vitro Treg conversion through TGF-β, and TGF-
β neutralization abrogated Treg accumulation at the tumor site
(77). Human leukemic cells converted in vitro non-Treg into Treg
through the tumor cell-restricted IDO activity, and IDO blockade
prevented pTreg induction in vivo in a leukemia mouse model (78).
A confirmation of extensive pTreg infiltration in murine tumors
has been recently obtained thanks to the recent discovery of Nrp-1
as a tTreg-restricted marker (61, 62). The analysis of Nrp-1 expres-
sion has indeed revealed that Nrp-1-negative bona fide pTreg cells
were significantly enriched at tumor site compared to spleen, rang-
ing around 40–90% of total tumor-infiltrating Treg depending on
the tumor type (61). These Nrp-1-negative cells also presented a
gene signature (Helioslow, SWAP-70low, and Dapl1high) compati-
ble with the pTreg identity (61). Unfortunately, human Treg do not
express Nrp-1 (63), thus this marker cannot be used to estimate
the relative contribution of tTreg or pTreg in human cancers.
Frontiers in Immunology | Immunological Tolerance August 2013 | Volume 4 | Article 247 | 4
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Burocchi et al. tTreg and pTreg in cancer
DEVELOPMENTAL AND FUNCTIONAL RELATIONS BETWEEN
pTreg AND tTreg IN CANCER
pTreg DEVELOPMENT AND tTreg EXPANSION AS INDEPENDENT
PROCESSES
Many attempts have been made to understand whether tTreg accu-
mulation and pTreg development are mutually exclusive or rather
cooperative in establishing immune suppression. The evidence
that tTreg may “educate” Tconv to convert into Treg through the
secretion of cytokines, such as TGF-β and IL-10 (79), may support
the latter possibility. This event would generate a cascade of sup-
pressive function transmitted from Treg to bystander cells, estab-
lishing a loop of immunosuppression, reminiscent of a phenom-
enon called as “infectious tolerance” (80). Zhou and coworkers
have addressed this issue in the tumor setting, and have demon-
strated that tumor-antigen-specific pTreg could indeed arise from
Treg-depleted cells (adoptively transferred in mice carrying the
cognate antigen-expressing tumor), but that the extent of pTreg
induction was not affected by the concomitant presence of tTreg,
either exogenous (adoptively co-transferred) or endogenous (pre-
existing in the host) (81, 82). This result indicated that tTreg and
pTreg accumulate in tumors in a reciprocally independent fashion
and that “infectious tolerance” may play minor roles in shaping
the tumor-associated Treg pool.
A comprehensive scenario of Treg accumulation in tumors
should take into account, beside de novo conversion, the active
proliferation of not only tTreg but also pTreg. Proliferation plays
opposite roles in the differentiation of Tconv into pTreg ver-
sus the expansion of already differentiated pTreg. Regarding
the former aspect, we have demonstrated that Tconv prolifer-
ation was not required for their conversion into pTreg, since
CD25+Foxp3+ cells could develop in tumor-bearing mice from
CD25-depleted cells treated with an anti-proliferative agent (76).
A seminal study by Kretschmer and colleagues showed that
Tconv proliferation was not only dispensable but also detri-
mental to conversion: indeed, low levels of T cell proliferation,
in conditions of suboptimal antigen presentation, lack of co-
stimulation, and IL-2 paucity, favored TGF-β-mediated pTreg
induction, thus suggesting that an inverse relationship might
exist between Tconv proliferation and conversion into pTreg
(83). However, once developed, pTreg promptly proliferated in
response to experimental antigens (83) and, more importantly,
in response to tumor antigens (81, 82). Experiments performed
in CNS1-mutated mice, which are genetically unable to gen-
erate pTreg, have shown that pTreg and tTreg may occupy dis-
tinct “niches”: indeed, the efficiency of pTreg differentiation
from Tconv was higher when those Tconv were co-transferred, in
lymphopenic recipients, with a CNS1-deficient (non-containing
pTreg) compared to a CNS1-sufficient (containing pTreg) coun-
terpart, suggesting that not only the tTreg pool, but also the
pTreg niche, may be controlled by autonomous homeostatic
mechanisms (84).
DIVISION OF LABOR BETWEEN tTreg AND pTreg IN CANCER
Both tTreg and pTreg have been generally recognized as immune
suppressive cells in a variety of in vivo and in vitro experimen-
tal settings (12). However, whether the two subsets are endowed
with peculiar activities remains unclear and is a matter of intense
investigation.
Gene expression profiling revealed that the pTreg and tTreg sig-
natures were mostly overlapping but also presented some differen-
tially expressed genes, encoding for proteins involved in Treg sup-
pressive function, suggesting that pTreg may preferentially exploit
different molecules and related mechanisms to exert suppression
(64–66). The Nrp-1 itself is not only a marker discriminating
murine tTreg from pTreg, but also plays a role in Treg suppres-
sion: since this molecule prolongs Treg interactions with immature
dendritic cells, tTreg may benefit from this pathway in preferen-
tially modulating dendritic cell and cognate T cell activation (22).
Many data suggest that pTreg may be specialized suppressors of
immune responses at interfaces with external environments, such
as airways, gut, and maternal-fetal interface (64, 84–87). Of note,
a peculiar Treg suppressive molecule, IL-10, plays crucial roles at
environmental interfaces, therefore pTreg may perform their spe-
cialized activity through IL-10 secretion (34, 88). IL-10 is critically
involved in the establishment of tumor-associated immune sup-
pression, and we have clearly demonstrated IL-10 production by
around 40% of tumor-infiltrating Treg in murine transplanted
tumors (36). It would be interesting to understand whether the
fraction of IL-10-producing Treg is enriched in pTreg, rather than
tTreg, in tumors. One study has directly addressed the issue of
induced Treg functional specialization in tumors, by generating
in vitro tumor-specific iTreg and co-culturing these cells, or tTreg
as control, with NK cells: these authors found that iTreg and tTreg
equally suppressed IL-2-induced NK activation, but only iTreg
were endowed with the surprising ability not to suppress, but
to enhance, NK cytotoxicity induced by tumor target cell con-
tact (89). This observation may speak in favor of differential
roles played by tTreg and pTreg in cancer, with the former more
involved in preventing target cell-independent, and possibly self-
directed, unwanted immune responses, and the latter concurrently
enhancing tumor-specific immunity.
This division of labor may result in the progressive shaping of
the immune response toward an effective anti-tumor immunity
with minimal side effects. Such dichotomy is also reminiscent
of the double role played by Treg in different cancers, accord-
ing to the hypothesis that high Treg frequency is associated to
poor or good prognosis in non-inflammatory or inflammatory
cancer onset, respectively (13, 47). In the former case, i.e., non-
inflammatory cancers in which protective type-1 responses are
suppressed by high Treg infiltration, Treg may mainly recognize
tumor-associated self-antigens, and mostly include tTreg; con-
versely, in the case of inflammatory cancers, related to chronic
low-dose type-17 cytokines, which are typical of mucosal tissues,
high numbers of pTreg may suppress pro-tumoral inflammation
through IL-10, relevantly produced by pTreg at those sites. We
are tempting to speculate that tTreg may dominate in suppressing
anti-tumor type-1 responses, while pTreg may prevail in shaping
pro-tumor type-2 and type-17 inflammatory responses. Notably,
the prototypical example of an inflammation-related tumor in
which Treg accumulation associates to good prognosis is CRC
(50), developing in the gastrointestinal mucosa, in which immune
tolerance is under the control of pTreg (84).
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ANTIGEN SPECIFICITY OF tTreg VERSUS pTreg IN CANCER
Antigen recognition may play a crucial role in dictating whether
tTreg or pTreg will prevail in the tumor context. Controversy still
exists on the antigen specificity of these two populations. On the
one side, tTreg are generally believed to recognize self-antigens
encountered during thymic selection (90). On the other side,
pTreg, deriving from Tconv, are thought to display the same TCR
repertoire of Tconv and thus to mainly recognize foreign antigens.
Indeed, only a small overlap exists between TCR repertoires of
pTreg and tTreg (66), and pTreg are believed to recognize non-
self-antigens such as commensal microbiota, allergens, and fetal
alloantigens (84, 87).
Tumor cells can express a variety of antigens that can be broadly
classified into: (i) self-antigens physiologically expressed as in the
tissue of origin, (ii) self-antigens aberrantly expressed, in terms of
expression level, developmental stage, or histotype (called tumor-
associated antigens or TAAs), and (iii) neo-antigens uniquely
expressed by tumor cells, mostly derived from oncogenic muta-
tions (named tumor-specific antigens or TSAs). Based on the
above considerations, self-antigens and TAA should be recognized
by tTreg, while TSA would induce and activate pTreg. However, a
complex picture arises from studies analyzing the TCR specificity
of tumor-associated Treg.
Treg can recognize TAA and TSA in tumors
In different tumor models, TCR-transgenic Treg have been shown
to promptly proliferate in response to the cognate antigen specif-
ically expressed by tumor cells, suggesting that Treg can undergo
tumor-antigen-driven activation and expansion (74, 81, 82, 91).
Antigen presentation in the tumor context may favor Treg expan-
sion: in a mouse model of spontaneous prostate cancer, an efficient
Treg induction/expansion occurred only when TCR-transgenic,
antigen-specific CD4 T cells encountered the cognate antigen
expressed in the context of prostate cancer cells, rather than non-
transformed cells or viral vector-infected cells (91). In this model,
TAA-specific Treg were recognized as pTreg induced in vivo in a
TGF-β-independent fashion.
This evidence of TAA-responding Treg has been confirmed in
human tumors. CD4 clones derived from cancer patients resulted
to be regulatory cells and to recognize peptides derived from
TAAs, such as LAGE1 (92), ARTC1 (93), TRAG-3, NY-ESO-
1 (94–96), Melan-A (97), survivin, TRP1, and gp100 (94) in
melanoma patients, and WT-1 in leukemia patients (98). By using
MHCII/peptide tetramer technology, other authors failed to detect
Treg specific for NY-ESO-1 in the peripheral blood of ovarian
cancer patients (99). Bonertz et al. developed an in vitro system
to screen the suppressive function of Treg in response to single
peptides and, with this approach, could detect Treg specific for
several TAA in the peripheral blood of colon carcinoma patients
but not in healthy donors; notably, Treg depletion in vitro unveiled
TAA-specific Tconv responses (100).
The possibility that tumor-associated Treg may recognize not
only TAA but also TSA is demonstrated by the observation that
Treg specific for exogenous viral antigens, acting as TSA, may arise
in virus-related cancers. Treg clones specific for human papilloma
virus (HPV), and suppressing the cognate antigen-directed T cell
response, have been obtained from tumor-draining lymph nodes
and tumor biopsies of cervical cancer patients (101). Treg clones
specific for antigens of the Epstein–Barr virus (EBV), associated
to several hematological and solid malignancies, can be generated
from the peripheral blood of healthy donors (102).
Treg can recognize self-antigens in tumors
Several data in mouse models confirm that Treg responding to self-
antigens can play a role in suppressing the anti-tumor responses.
Immunization with serologically defined auto-antigens was found
to enhance tumor growth in different mouse models, and this
event was dependent on the expansion of Treg responding to
those self-antigens (103). This study confirmed that self-antigens-
specific Treg could suppress anti-tumor immunity, but did not
explore the Treg response to self-antigens expressed by tumor cells
themselves during tumor progression. This issue has been instead
addressed in an experimental model in which a foreign antigen,
artificially expressed in transgenic mice under tissue-specific pro-
moter, was seen (peripherally and/or thymically) by the immune
system as a self-antigen and elicited the generation of a pool of
memory Treg specific for that antigen (74). If those mice were
injected with the cognate antigen-bearing tumor, the memory Treg
pool specific for that self-antigen was hugely expanded in tumors
and tumor-draining lymph nodes, confirming that self-specific
Treg can respond to self-antigens expressed by tumor cells (74).
A seminal paper has recently reported the immunoscope analy-
sis of Treg infiltrating spontaneous prostate tumors in a mouse
transgenic model, and described the clonal enrichment of a sin-
gle Treg specificity that was directed not to a unique TSA but to
a self-antigen expressed also by normal prostate cells (104). The
development of Treg specific for peripheral tissue-restricted self-
antigens occurred in the thymus under the control of the Aire
molecule, which allows the expression of peripheral antigens in
thymic epithelial cells (104). These findings clearly demonstrate
that Treg can recognize self-antigens in cancer and suggest that
maintaining self-antigen expression may help transformed cells
to overcome the immune surveillance through self-specific Treg
expansion.
Repertoire analysis as an estimation of pTreg/tTreg balance
The direct comparison between the repertoires of tumor-
associated Treg and Tconv may help understanding the processes
underlying Treg enrichment in cancer. Some authors have reported
that the analysis of TCR diversity (performed with the immuno-
scope technology) showed that Treg infiltrating murine trans-
planted tumors displayed a biased TCR repertoire toward “pub-
lic” CDR3 sequences (i.e., shared by different mice), suggesting
Treg intra-tumor clonal expansion driven by the recognition of
dominant antigens (105). Also tumor-infiltrating activated Tconv
showed a biased TCR repertoire, but it was distinct from the Treg
spectrum, and the minimal overlap between the two subsets was
mainly confined to “private” specificities (105). By using a simi-
lar approach, others have reported distinct and not overlapping
TCR repertoires of Treg and Tconv infiltrating prostate tumors in
a genetically engineered mouse model of spontaneous prostate
carcinogenesis (104). Lack of overlap between Tconv and Treg
repertoires was also found in tumors and tumor-draining lymph
nodes in a mouse model of chemical carcinogenesis (106). Overall,
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the lack of overlap between Treg and Tconv has been interpreted in
many cases as the result of negligible pTreg conversion at the tumor
site; however, pTreg and tTreg may share more specificities than
expected, since tTreg-associated antigens may preferentially drive
Tconv fate decision toward the conversion into pTreg rather than
toward the conventional activation; moreover, already established
pTreg may then undergo intra-tumor clonal expansion together
with tTreg in response to the same antigens. Therefore, the overall
overlap between Tconv and Treg specificities may not accurately
estimate the extent of pTreg induction in tumors. Indeed, in one
study performed in advanced melanoma patients, TAA-specific
TCRs, expressed by tumor Treg clones, could be detected in both
Treg and Tconv populations, demonstrating that TAA-specific Treg
may be comprised of pTreg derived from the conversion of Tconv
(95).
Indirect data support the notion that TAA-specific Treg may
contain pTreg. TAA-specific Treg clones, obtained from patients
with advanced melanoma, suppressed in vitro the cognate antigen-
specific T cell response, but produced high levels of Th1 and/or
Th2 cytokines (95), and showed low FOXP3 expression and TSDR
demethylation, indicating that these cells may represent an incom-
pletely uncommitted Treg population, which more likely belongs
to the pTreg than to the tTreg pool (95).
A recent study has directly evaluated the consequences of pTreg
and tTreg antigen specificities in tumor-bearing hosts. Indeed,
Schreiber et al. have shown that, if purified polyclonal tTreg and
Tconv, differentially labeled with green or red fluorescence, were co-
transferred in CD4-null mice, the tTreg progeny exceeded the newly
Tconv-derived pTreg population in tumor-draining lymph nodes as
well as in the spleen; conversely, when transgenic, tumor-antigen-
specific, tTreg and Tconv were injected, tTreg and pTreg reached
comparable frequencies in tumor-draining lymph nodes (107).
These results suggest that tTreg and pTreg are mostly specific for
self- or tumor-antigens respectively, and that the balance between
pTreg and tTreg may be fine-tuned by the relative prevalence of
TSAs versus self-antigens expressed by tumor cells.
HETEROGENEITY AND PLASTICITY OF tTreg AND pTreg
Treg HETEROGENEITY IN CANCER: RELATIONS WITH THE pTreg/tTreg
DICHOTOMY
During the latest years, it has become increasingly clear that
Treg, meant as Foxp3-positive cells, are not a homogeneous lin-
eage, but rather represent a mixture of subpopulations. Indeed,
beside the tTreg/pTreg distinction based on their developmental
origin, diverse Treg subsets can be identified endowed with pecu-
liar features in terms of suppression, proliferation, and stability,
even though not properly classifiable as developmentally distinct
lineages (Figure 2). Tumor microenvironmental signals may dif-
ferentially affect these subsets, thus shaping Treg heterogeneity to
the advantage of tumor progression.
Treg stability and epigenetic commitment in cancer
Foxp3 inherent stability, rather than Foxp3 expression in a given
moment and tissue, is intimately linked to an actual commit-
ment to the Treg lineage and therefore to the maintenance of
immune suppression. Pioneer studies have demonstrated that
Foxp3 stability is strictly related to an epigenetic imprinting of
FIGURE 2 | Functional dynamics of tTreg and pTreg in cancer. This picture
summarizes development, heterogeneity, plasticity, antigen specificity, and
function of pTreg and tTreg in cancer. Activated Treg, which are epigenetically
committed and mostly self- and TAA-specific, can transiently lose Foxp3
without methylating TSDR thus becoming latent Treg; in some conditions,
they can acquire T-bet expression thus becoming specialized suppressors,
detrimental to the anti-tumor type-1 response. Activated Tconv, mostly
foreign (TSA) antigen-specific, can promiscuously express Foxp3 without
demethylating TSDR. However, a fraction (CD25+, or CD39+) of activated
Tconv can convert into pTreg, progressively moving from an uncommitted to a
committed stage. Through IL-10, committed pTreg can suppress pro-tumoral
inflammatory and type-17 responses, thus exerting beneficial roles for the
host in some cancer types. In some contexts, uncommitted pTreg (and
possibly activated Tconv) can move back to exTreg stage, acquiring the ability
to produce inflammatory cytokines. Therefore, in some tumors such as
colon cancer, Th17-like Treg may foster type-17 inflammation thus supporting
tumor growth; in other tumor contexts, Th1-like Treg can favor type-1
responses that rather block tumor growth. Green, cells specific for
self-antigens and TAA; light blue, cells specific for foreign antigens including
TSA. Yellow dash, demethylated TSDR; blue dash, methylated TSDR. Red
“F” in yellow circles, stable Foxp3; yellow “F” in empty circles, unstable
Foxp3. Dashed arrows, unclear events. Orange rounded arrows,
proliferation in the tTreg or the pTreg homeostatic niche. Light green frames,
conditions in which Treg are beneficial to the host; light orange frames,
conditions in which Treg are detrimental to the host.
CpG demethylation in the TSDR region of the Foxp3 locus (67, 86,
108). TSDR demethylation was then recognized as the mechanism
featuring the distinction between committed (demethylated) and
uncommitted (methylated) Treg, irrespective of Foxp3 expression
(9). Controversy exists on whether pTreg show complete or partial
TSDR demethylation and can then be considered as committed
Treg. Many studies show that iTreg have a partially or completely
methylated TSDR (9, 67–69), while pTreg have been described as
TSDR-demethylated (68), TSDR-methylated (66), or as a mixed
population of stable and unstable cells, characterized by CD25
high or low expression respectively (69).
Few data exist on the extent of TSDR demethylation in tumor-
associated Treg. The frequency of TSDR-demethylated cells is
higher in peripheral and intratumoral leukocytes of lung, colon,
prostate, or breast cancer patients, in relation to a higher Treg
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frequency as determined by flow cytometry or immunohistochem-
istry (109). Of note, the extent of TSDR demethylation in CRC
patients was only slightly higher than in healthy volunteers, in con-
trast to the significantly increased Treg frequency in these samples
shown by previous studies (110, 111). This discrepancy may be
explained with the peculiar nature of this inflammation-related
and mucosal tissue-located cancer, in which the inflammatory
response may specifically involve pTreg, possibly containing more
uncommitted (TSDR-methylated) cells than tTreg.
The evaluation of TSDR demethylation has been used as a
reliable analytical tool for the estimation of committed Treg in
some tumor conditions and therapies. An increased frequency
of epigenetically committed (TSDR-demethylated) Treg has been
determined in tumor-infiltrating cells of ovarian, colorectal, and
bronchial cancers compared to non-tumoral tissue counterparts
(112). TSDR demethylation was decreased in the peripheral blood
of metastatic renal carcinoma patients receiving tumor vaccina-
tion (113), and increased in patients treated with dendritic cell
vaccination and cytokine therapy (114).
Treg functional dynamics in cancer
The idea of Foxp3 as the master transcription factor of Treg lin-
eage has been challenged by the observation that some Treg features
are Foxp3-independent, and that Foxp3 plays Treg-unrelated func-
tions (115). This is especially true for human FOXP3-positive cells,
since human activated Tconv can transiently express this transcrip-
tion factor that acts as an intrinsic T cell regulator (116). The
concomitant analysis of CD45RA and FOXP3 in human Treg in
both physiological and pathological contexts allowed delineating
a classification into three subsets: CD45RA+FOXP3low resting Treg
(rTreg), CD45RA−FOXP3low non-Treg, and CD45RA−FOXP3high
(CD45RO+) activated Treg (aTreg), endowed with different poten-
tials of proliferation, suppression, stability, and plasticity (117).
Whether each subset mainly contains tTreg or pTreg is unclear.
While rTreg were recognized as CD31+ recent thymic emigrants,
thus belonging to the tTreg pool, aTreg can be considered as a
mixed population of activated tTreg (derived from rTreg) and pTreg
(derived from non-Treg or Tconv). The CD45RA−FOXP3low non-
Treg subset may represent a mixture of activated Tconv (promis-
cuously and unstably expressing FOXP3), latent Treg (transiently
downregulating FOXP3), and recently converted pTreg (117).
The three human Treg subsets can be differentially expanded
in distinct pathologies. In conditions characterized by exacer-
bated immune responses, such as autoimmune diseases, rTreg
and non-Treg are expanded; conversely, in diseases associated to
immune unresponsiveness, such as sarcoidosis, the aTreg subset
is instead enriched in the peripheral blood (117). The tumor
context, which conceivably belongs to the latter category, should
be characterized by aTreg expansion. In line with this hypothe-
sis, CD45RO+FOXP3high aTreg were found significantly expanded
in the peripheral blood, and much more at the tumor site, in
patients with malignant melanoma (118). Also the non-Treg and
the rTreg fractions were increased, but only in the peripheral blood,
in cancer patients compared to healthy controls, and both subsets
positively correlated with tumor progression (118). The non-Treg
pool produced some IFN-γ and its frequency returned to normal
levels after tumor removal, thus probably representing aberrantly
activated Tconv, or Treg with attenuated FOXP3 activity (118). A
much deeper knowledge on Treg dynamics in cancer is needed to
better understand the role played by each specialized component
in suppressing anti-tumor type-1, or pro-tumor inflammatory,
responses.
Treg subsets specified by functional/developmental markers
Several surface or intracellular markers have been suggested
to identify Treg subsets endowed with peculiar abilities other
than suppressive functions. A portion of human Treg with an
effector/memory-like phenotype (26, 119, 120) expresses CD39,
which has been proposed as a target to enrich human suppressive
Treg (119). CD39 was found overrepresented in peripheral and
tumor-infiltrating Treg from HNSCC, and was further increased
in patients with advanced-stage disease or after radiochemother-
apy (120, 121). CD39 is also expressed by a Tconv subset, which
produces lower levels of pro-inflammatory cytokines than the
bulk Tconv population, and is more prone to convert, at least
in vitro, into Treg (120). Both CD39+ Treg and CD39+ Tconv were
enriched in peripheral blood, and further increased at tumor site,
in HNSCC patients, and a positive correlation existed between
frequencies of these two populations (120). Therefore, these data
suggest that tumor-associated CD39+ Tconv may represent a reser-
voir of CD39+ Treg precursors. As a consequence, it could be
suggested that CD39+ Treg may include both tTreg and pTreg, and
that both Treg subsets can exploit the CD39-mediated suppressive
mechanisms of ATP degradation and adenosine generation.
Not only the functional arms of suppression, but also the acti-
vation requirements may differ in tTreg and pTreg: for instance,
TNFR2 expression is needed to activate tTreg but not iTreg suppres-
sive ability in experimental colitis (122). Of note, TNFR2-positive
Treg have been found enriched in murine tumors, in association
with a higher suppressive ability, ex vivo, in the standard sup-
pression assay (123). In a mouse model of metastatic melanoma,
TNF-α caused enhanced tumor progression through the TNFR2-
mediated Treg expansion at the site of metastasis (124). These data
suggest that TNFR2 expression may label tumor-infiltrating Treg
of thymic origin, and that TNF-α at the tumors site may prefer-
entially expand and activate tTreg. Supporting the idea that tTreg
may represent more stable cells, TNFR2 was found to be involved
in the maintenance of Foxp3 stability in mouse models of inflam-
mation (125). Also in human peripheral blood, CD25 and TNFR2
co-expression identifies cells highly expressing FOXP3, showing
an effector/memory phenotype and strong suppression, ex vivo
(126). The TNF-α/TNFR2 pathway may amplify Treg activation
also through the induction of a NF-kB-driven transcriptional pro-
gram enriched for other members of TNF superfamily, such as
4-1BB, FAS, and OX40 (127).
The early idea that Helios could differentiate tTreg from pTreg
(59, 128) prompted the use of this marker in delineating tTreg
accumulation in cancer. The vast majority of tumor-infiltrating
Treg were found to express Helios in a mouse model of glioblas-
toma (129), in glioblastoma multiforme patients (129), and renal
cell carcinoma patients (130). However, the value of Helios as uni-
vocal marker of tTreg has been questioned by other studies that
showed Helios also expressed in pTreg (60, 131), and in associ-
ation to Treg suppression (128, 131) and commitment. Indeed,
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Helios−FOXP3+ cells freshly isolated from healthy donors or
autoimmune disease patients showed decreased TSDR demethyla-
tion compared to Helios+FOXP3+ (132, 133), and also displayed
a higher plasticity in terms of cytokine production (133). In a
murine transplanted tumor model, tumor-infiltrating Treg were
enriched in Helios+ cells, representing the subset with the high-
est proliferative potential (as shown by Ki67 staining) (131). In
summary, the well-recognized enrichment of Helios+ Treg in sev-
eral human and mouse tumors may be attributed, rather than to
preferential attraction and expansion of tTreg, to the tumor-driven
local activation and/or commitment of both tTreg and pTreg.
SPECIALIZATION AND PLASTICITY OF tTreg/pTreg IN CANCER
It is now well established that Treg (or better, their specific sub-
sets) adapt their molecular programs to optimize their in vivo
suppressive function in distinct inflammatory milieus, which may
be alternatively dominated by Th1, Th2, Th17, or TFH responses.
Strikingly, these Treg specialized programs are orchestrated by
the same transcription factors that drive the polarization of the
targeted T-helper subset: therefore, T-bet, IRF4, Stat3, and Bcl6
expression are respectively and selectively required for the Treg spe-
cialized suppression of Th1 (134, 135), Th2 (136), Th17 (137), and
TFH (138, 139) responses. Indeed, by acquiring master T-helper
genes, Treg may gain the expression of chemokine receptors driving
the recruitment of specialized Treg into inflamed tissues. However,
in some contexts, Treg (or, again, some Treg subsets) can express not
only T-helper-related transcription factors and migratory mol-
ecules, but also cytokines such as IFN-γ or IL-17, thus turning
from specialized suppressors into so-called Th1-like or Th17-like
Treg that may rather contribute to inflammation (140). Some data,
mostly from mouse experimental models, suggest that such Treg
plasticity is not a lineage reprograming of committed Treg, which
appear instead quite stable; rather, Th1-like or Th17-like Treg may
derive from uncommitted cells expanded in inflammatory condi-
tions (69, 141). However, other studies have shown that in both
mouse and human pathologies Treg can produce relevant amounts
of type-1 and type-17 cytokines even though preserving Foxp3
expression (142–146).
Th17-like Treg in cancer
Regulatory T cells may shift to a Th17-like phenotype in inflamed
microenvironments dominated by type-17 cytokines, thus favor-
ing, rather than suppressing, pro-tumoral mechanisms of chronic
inflammation. According to this idea, human Treg have been found
to spontaneously secrete IL-17 in the intestine of patients carrying
inflammatory bowel disease (145, 147) and colon carcinoma (147).
In epithelial ovarian cancer, a malignancy associated to chronic
inflammation, Tconv were found to secrete high levels of IL-17 (and
other cytokines) when cultured ex vivo with IL-2; under similar
conditions, tumor-infiltrating Treg were prone to FOXP3 down-
regulation, attenuation of suppressive function, and prompt IL-17
production (148). In human lung adenocarcinoma, FOXP3 mes-
sage amounts correlated with Th17-related transcripts enriched
at the tumor site, where IL-17 antagonized the development of
the anti-tumor, T-bet-dependent, Th1 response (149). Myeloid
antigen-presenting cells and cytokines such as IL-2, TGF-β, IL-
1, IL-23, and IL-6 may initiate Treg polarization into Th17-like
cells in these tumor contexts (147–149). In a mouse model of
hereditary colon polyposis, as well as in human colon cancer, the
Th17-like Treg co-expressed the Th17-related transcription factor
ROR-γt, and fostered tumor progression, also through the pro-
motion of mast cell local expansion (150, 151). This study clearly
demonstrated that microenvironmental signals could direct Treg
plasticity toward pro-inflammatory and pro-tumoral activities.
One group has demonstrated that Th17-like Treg can also arise
in experimental tumors as an outcome of vaccination strategies
(152). In this study, vaccination with antigen plus TLR-9 lig-
and induced Treg reprograming into polyfunctional T-helper-like
cells, producing a wide array of cytokines including IL-2, TNF-
α, and IL-17, and expressing cell-surface CD40L, thus providing
efficient T cell help for tumor-antigen cross-presentation and
development of anti-tumor response (152). The IDO immuno-
suppressive enzymatic activity was responsible for preventing this
anti-tumor Treg polarization, which was instead enhanced using
an IDO blocker (152).
Little data exist on the precursors of Th17-like Treg in cancer. In
the peripheral blood of healthy subjects, the CD45RA−FOXP3low
non-Treg subset was found enriched in Th17-related transcripts
and in cells actively secreting IL-17, even at higher levels than
naïve or memory Tconv, a data suggesting that this population
contains Th17 or Th17-like precursors (117). It would be interest-
ing to understand whether the Th17 potential resides, within the
non-Treg gate, in activated Tconv, in latent Treg, and/or in recently
induced pTreg, possibly co-expressing FOXP3 and RORγt and thus
pre-committed to the Th17 lineage.
Th1-like Treg in cancer
Pioneer studies from Koch and colleagues demonstrated that, fol-
lowing exposure to IFN-γ in Th1-dominated microenvironments,
a subset of Treg can up-regulate the Th1-related transcription
factor T-bet, which drives Treg expansion, migration (CXCR3-
mediated), and function specifically during type-1 inflammation
(134). Further experiments have shed light on the developmen-
tal requirements and the alternative fates of murine T-bet+ Treg:
following IFN-γ stimulation, Treg could gain T-bet expression but
failed to fully polarize into IFN-γ-producing Th1-like Treg, due
to an impaired Treg susceptibility to IL-12. Indeed, IL-12 receptor
β2, which is inducible in Tconv in an IFN-γ- and T-bet-dependent
fashion, is epigenetically inaccessible in Treg (135). Only long-
lasting IFN-γ preconditioning could unlock IL-12 responsiveness,
thus allowing the complete Treg polarization into Th1-like cells
(135). Presumably, in contexts characterized by chronic IFN-γ
and IL-12 abundance, such as autoimmune, inflammatory, and
viral diseases, Treg will be oriented to a full reprograming into
Th1-like cells. Supporting this idea, IFN-γ-producing Treg have
been reported in mouse models of graft-versus-host disease (153),
viral (154) or parasite (142) infection, in human multiple sclerosis
(144), and diabetes (146, 155). In one of these systems, IFN-γ-
producing Treg were recognized to be specific for a foreign (viral)
antigen (154). Whether such Th1-like Treg can be yet considered
as classical regulatory cells is still debated. One study has shown
that in vitro polarized Th1-like Treg were less suppressive than con-
ventional Treg in the standard in vitro suppression assay, and that
suppression could be partially rescued with concomitant IL-10
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and IFN-γ neutralization (144). Another study has proven that
IFN-γ-producing human iTreg were equally functional as natural
Treg in suppressing both proliferation and cytokine production of
responder T cells (156). In a mouse model of graft-versus-host
disease, IFN-γ produced by stable (TSDR-demethylated) Treg was
shown to be even required for Treg protective effect (153), sug-
gesting that IFN-γ-releasing Treg can display in vivo unexpected
functions depending on the context.
Conversely, it could be envisaged that, in the tumor con-
text, the low levels of IFN-γ derived from Tconv, NK, and CD8
cells, and the paucity of IL-12 production by tumor-associated
APCs, may concur to induce a pool of Treg expressing T-bet
but not secreting IFN-γ, thus specialized in suppressing anti-
tumor type-1 immunity. In line with this possibility, TAA-specific
Tconv, but not TAA-specific Treg, produced IFN-γ in patients with
epithelial ovarian cancer (99). In both healthy subjects (117) and
malignant melanoma patients (118), IFN-γ-producing cells were
enriched within the circulating CD45RA−FOXP3low (CD45RO+)
non-Treg subset, mostly including activated Tconv and/or uncom-
mitted Treg. Conversely, in ovarian cancer, tumor-infiltrating Treg
were enriched in CXCR3+ cells, highly expressing T-bet but
poorly producing IFN-γ, and strongly suppressing Th1 response
ex vivo (157). Tumor-associated CXCR3+ Treg were mostly Helios-
positive, and T-bet+ Treg could be generated in vitro by cul-
turing CD45RA+CCR7+ rTreg (mostly containing tTreg) under
Th1-polarizing conditions (157), suggesting their derivation from
committed tTreg. This finding was in accordance to Koch et al. who
showed that T-bet+ Treg derived from T-bet− Treg, rather than
from activated Tconv (134). These data support the idea that tTreg,
rather than pTreg, may contain the precursors for Th1-specialized
suppressors, thus playing critical roles in suppressing protective
responses in tumors whose high Treg frequency correlates with
poor prognosis (13).
Some therapeutic interventions can force tumor-associated
Treg toward a fully differentiated Th1-like phenotype. For instance,
circulating Treg from melanoma patients showed significantly
higher IFN-γ secretion following a protocol of tumor peptide vac-
cination plus IL-2 and cyclophosphamide, in line with enhanced
serum IL-12 (158). On the whole, these data suggest that, especially
in the human system, the transition from T-bet+ Treg, special-
ized Th1 suppressors, into T-bet+ IFN-γ+ Treg, Th1-like plastic
cells, may not only depend on the availability and the responsive-
ness to exogenous stimuli, but may differentially occur in distinct
Treg precursors: on the one side, tTreg, enriched in committed
and self-specific cells, may be forced to arrest to the specializa-
tion (T-bet+) endpoint; on the other side, pTreg, containing less
committed and foreign antigens-specific cells, may be more prone
to the complete reprograming into pro-inflammatory (T-bet+
IFN-γ+) cells. Future studies will elucidate the mechanisms by
which different growing tumors may favor the expansion of pro-
tumoral specialized Th1 suppressors or the induction of Th1-like
plastic Treg.
IMPLICATIONS FOR CANCER IMMUNOTHERAPY
The initial enthusiasm on the use of therapeutic cancer vaccines
has been soon disappointed by the observation of a low response
rate in many trials (159). After the discovery of Treg as potent
immune suppressive cells hampering the establishment of anti-
tumor immunity, it soon became clear that anti-tumor vaccination
might fail to elicit an effective immune response and to achieve suc-
cessful tumor eradication, because of the immune suppressive bar-
rier created by Treg. In addition, since Treg may recognize TAA and
TSA at higher frequency than Tconv, tumor-antigen-based vaccines
may expand/induce Treg rather than effector cells, thus inhibiting
rather than boosting the anti-tumor response. Indeed, Zhou et al.
first demonstrated that TCR-transgenic CD4 T cells specific for
a TAA, adoptively transferred into mice bearing TAA-expressing
tumor cells, proliferated extensively after administration of a ther-
apeutic tumor vaccine (in the form of a recombinant vaccinia
virus encoding the antigen), but tumor-antigen-experienced cells
were mostly regulatory cells, ex vivo suppressive, and anergic to
subsequent stimulation (81).
In cancer patients receiving tumor-antigen vaccination, the
expansion of antigen-specific Treg has been documented. Circu-
lating NY-ESO-1-specific Treg spontaneously develop in late-stage
melanoma patients and are expanded following immunization
with NY-ESO-1 protein supplemented with adjuvants (96). Ther-
apeutic vaccination with an HPV synthetic long peptide vaccine,
administered to patients with HPV-positive cervical carcinoma,
induced both CD8 and CD4 T cell immunity, but also enhanced
the HPV-specific Treg pool (160). The pool of vaccine-specific
Treg may derive not only from the expansion of pre-existing
tumor-antigen-specific clones, but also from de novo generation of
vaccine-specific pTreg. This is suggested by results obtained vacci-
nating melanoma patients with an HLA-DP4-restricted MAGE-
A3 peptide: in this setting, a subset of vaccine-specific Treg
becomes detectable only after vaccination (161). Vaccine-elicited
Treg showed some degree of heterogeneity: out of five CD25+ regu-
latory clones isolated from vaccinated patients, four expressed high
FOXP3 mRNA levels, produced TGF-β, and showed demethylated
TSDR; one clone expressed less FOXP3, had methylated TSDR
and produced some Th2 cytokines (161). These data suggest that
antigen-specific Treg, induced in the periphery following anti-
gen exposure and thus recognizable as pTreg, can contain both
committed and uncommitted cells.
The concomitant and detrimental Treg expansion in anti-
tumor vaccination can be avoided by using CD8 T cell-targeted
approaches. A melanoma vaccination protocol based on an
MHCI-restricted Melan-A peptide significantly decreased the fre-
quency of Melan-A-specific Treg, in association with an improved
and more diverse Th1 response (97).
Some attempts have also been made to combine active
immunotherapy with Treg depletion or functional blockade. Sev-
eral studies showed that depletion of CD25+ cells in vivo in cancer
patients could enhance the tumor-specific T cell responses induced
by cancer vaccines (15). However, CD25-directed strategies may
fail to achieve sustained results, since activated effector cells may
be concomitantly eliminated and pTreg may replenish the Treg
pool after depletion (15). Interestingly, a recent study has demon-
strated that different Treg-depleting agents, either CD25-targeted
(IL-2/diphtheria toxin fusion protein, or anti-CD25 antibody) or
not (low-dose cyclophosphamide), failed to consistently elimi-
nate more than 50% of committed Treg, as identified by TSDR
demethylation (162).
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Therefore, alternative strategies are needed to counteract the
“hard core” of immune suppression that is represented by epi-
genetically committed Treg. We have proposed in the past that
Treg functional inactivation, rather than depletion, may repre-
sent a successful strategy to prevent massive pTreg induction and
concomitantly block Treg suppression (15). This idea may be
corroborated by the observation that markers associated to Treg
suppressive functions, and therapeutically targetable, may show
enriched or restricted expression in epigenetically committed Treg.
For instance, GITR stimulation has been shown to attenuate Treg
suppression and favor the rejection of experimental tumors (163).
A recent study has demonstrated that GITR engagement in vivo
led to the downregulation of Foxp3 expression in intratumoral
Treg (164). Of note, GITR+ Treg were found enriched in Helios+
cells, representing highly committed Treg (131), thus GITR tar-
geting may preferentially block the strongest suppressors among
the Treg pool. A similar possibility could be envisaged for thera-
peutic strategies aimed at TNF-α/TNFR2 blockade, since this axis
may be mainly involved in the activation of more committed and
stable cells (122–126). Committed Treg may also be targeted by
virtue of their high proliferative potential: indeed, high prolifer-
ation rates, in terms of Ki67 positivity, were detected in healthy
subjects within the aTreg subset, enriched in stable and commit-
ted Treg (117), and also in murine tumor-infiltrating Helios+ Treg
(131). Therefore, treatments based on the depletion of prolifer-
ating cells, such as low-dose cyclophosphamide, may efficiently
target committed Treg.
An innovative way to improve immunotherapy would be to
reprogram tumor-associated Treg into fully armed effector cells,
which would then become “exTreg.” Different from other vaccine-
based approaches, Treg reprograming is expected to trigger anti-
tumor response very rapidly, since Treg are already located at
the tumor site and already tumor-antigen-experienced, thus not
requiring a de novo T cell priming. Therefore, exTreg may function
in an “innate-like” manner, promptly providing co-stimulatory
and pro-inflammatory signals when adequately modulated, before
a novel adaptive anti-tumor response develops (140). An exam-
ple of this approach has been proposed by Sharma et al. who
demonstrated that reprograming of mature pre-existing tumor-
associated Treg into CD40L-expressing helper effector cells was
needed to achieve tumor regression in a model of immunother-
apy combining antigen vaccination, TLR-9 stimulation, and IDO
blockade (152).
The above-discussed data overall indicate that tTreg and pTreg
may not be equally susceptible to functional reprograming,but this
dichotomy may turn into a benefit for the efficacy and safety of the
evoked response. Indeed, on the one hand, tTreg, predominantly
self-specific, highly committed, and hard to be reprogrammed into
T-helper-like cells, would be preserved, thus ensuring immune tol-
erance to self-antigens and maintaining systemic immune home-
ostasis. On the other hand, pTreg, mainly representing tumor-
specific and uncommitted cells, may be more easily converted
into exTreg, thus mounting an immediate helper and/or effector
response in a mostly tumor-antigen-specific fashion.
Reprograming into exTreg may be achieved by immunothera-
pies aimed at subverting the immune suppression mechanisms
established by innate cells in tumor microenvironments. For
instance, in the above-reported model of tumor vaccination,
CD40L upregulation by Treg following TLR-9 stimulation was
strictly dependent on host-derived MyD88 and IL-6 signals (152).
In melanoma patients, tumor peptide antigen vaccination com-
bined with low-dose cyclophosphamide and low-dose IL-2 evoked
Th1-like Treg accumulation, in line with a less tolerogenic microen-
vironment and with enhanced IL-12 availability (158). Of note,
in this system, depletion of proliferating (conceivably committed
and thymus-derived) Treg by means of cyclophosphamide allowed
the functional reshuffling of innate cells that in turn unveiled the
emergence of Th1-like exTreg.
However, it is arguable that microenvironmental rearrange-
ments would better accomplish full Treg reprograming with the
concomitant direct modulation of Treg activities, aimed especially
at enhancing Treg susceptibility to external signals. For instance,
expression of IL-12 receptor, which is epigenetically regulated
in Treg (135), could be artificially boosted by pharmacological
approaches. Also, targeting with monoclonal antibodies some
receptors expressed on Treg surface and correlated with Treg sta-
bility (such as TNFR2 and GITR) could result in enhancing Treg
propensity to reprograming. In line with this idea, treatment of
murine melanomas with a GITR agonistic antibody resulted in
the accumulation of exTreg at the tumor site (164). Suppressor of
cytokine signaling (SOCS) 1 and 2, which maintain Foxp3 stabil-
ity and prevent Treg polarization into effector cells (165, 166), may
be pharmacologically inhibited to unlock Treg responsiveness to
pro-inflammatory microenvironmental cytokines.
CONCLUSION
Even though discrimination between pTreg and tTreg by simple
surface phenotyping is not yet possible many pieces of evidence
indicate that both subsets contribute to the Treg pool condi-
tioning the tumor microenvironment. Nevertheless, the devel-
opment/expansion of pTreg and tTreg are independent processes,
possibly resulting from disparate antigens and signals, and their
activities seem characterized by very peculiar features in terms
of specificity, stability, and specialization. On the one side, tTreg
may expand at tumor site in response to self-antigens expressed
by tumor cells, mostly include committed (TSDR-demethylated)
Helios- and TNFR2-expressing cells, and contain the precursors
of specialized T-bet+ Th1-suppressing cells, thus representing not
only the guardians of systemic immune homeostasis but also the
“hard core”of tumor immune escape. On the other side, pTreg may
mostly develop following local encounter with TAA or TSA anti-
gens, possibly represent a mixed population of committed (TSDR-
demethylated) and uncommitted (TSDR-methylated) cells, and
are more prone to be reprogramed into Th1-like or Th17-like
effector cells. We envisage that future successful immunothera-
pies may not only target committed Treg but also favor “recycling”
uncommitted Treg into prompt anti-tumor effectors.
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